Pharma, Biotech and Generics Industry News

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-11T01:25:51.898Z • Permanent link

Regulatory pressures have intensified on Moderna Therapeutics, a leading biotech firm behind the mRNA-based COVID-19 vaccines, as the US Federal Trade Commission (FTC) has launched an investigation into the company's intellectual property practices. The probe is centered around Moderna's use of a novel mRNA technology, which the company claims to have developed independently. However, some critics argue that the firm may have relied on research conducted by academics and researchers at the University of Oxford.

In a statement released earlier this week, Moderna denied any wrongdoing and emphasized its commitment to upholding the highest standards of intellectual property protection. "We take our intellectual property rights very seriously and are confident that our practices comply with all applicable laws and regulations," the company said. The FTC's investigation is expected to focus on Moderna's patent filings and the company's licensing agreements with third-party firms.

Meanwhile, Pfizer and BioNTech, the developers of the Comirnaty COVID-19 vaccine, are facing similar scrutiny over their own intellectual property practices. The companies have been accused of overcharging for their vaccine and using aggressive tactics to restrict access to their technology. The European Union's competition regulator has launched a formal investigation into the matter, and the US Department of Justice has also received complaints from several firms alleging that Pfizer and BioNTech are engaging in anti-competitive behavior.

The fallout from the FTC's investigation into Moderna's intellectual property practices is likely to have far-reaching implications for the biotech industry as a whole. Companies like Pfizer and BioNTech, which have become giants in the COVID-19 vaccine market, are likely to face increased scrutiny over their business practices. The consequences for these firms could be significant, with potential fines and reputational damage on the line.

Regulatory bodies are also likely to take a closer look at the role of academic researchers and universities in the development of new medicines. Moderna's use of Oxford researchers, for example, has raised questions about the boundaries between industry and academia. The FTC's investigation is expected to shed light on these issues and inform policy debates about the relationship between industry and academia in the development of new medicines.

In the research community, the implications of the FTC's investigation are likely to be significant. Researchers who have contributed to the development of new medicines may face questions about their intellectual property rights and the terms of their collaborations with industry firms. The consequences for these researchers could be far-reaching, with potential implications for their careers and the future of medical research.